Get 40% Off
🚨 Markets Are Down. Unlock Undervalued StocksFind Stocks Now

New HDAC6 inhibitor shows promise in heart failure treatment

EditorEmilio Ghigini
Published 27/02/2024, 12:44 am
Updated 27/02/2024, 12:44 am
© Reuters.

SOUTH SAN FRANCISCO - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotech firm focused on heart disease treatments, has reported promising preclinical findings for its small molecule histone deacetylase 6 (HDAC6) inhibitors in treating heart failure with preserved ejection fraction (HFpEF).

The research, published in the journal Nature Communications on February 26, 2024, indicates that HDAC6 inhibition could address numerous biological characteristics of HFpEF.

The study utilized a murine model to replicate the disease state and demonstrated that the HDAC6 inhibitor, TYA-018, produced direct cardiac effects, such as improved diastolic relaxation, and systemic benefits, including metabolic and inflammatory factor normalization. Notably, when combined with the FDA-approved SGLT2 inhibitor empagliflozin, the treatment showed additional benefits over either therapy alone.

HFpEF, which affects over three million Americans, is characterized by the heart muscle's inability to relax normally, leading to diastolic dysfunction. Despite its prevalence, effective treatment options have been limited. Tenaya's TN-301, a specific HDAC6 inhibitor, has completed a Phase 1 trial, showing favorable safety and pharmacokinetics that support once-daily dosing.

Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya, emphasized the potential of HDAC6 inhibitors as a therapeutic strategy for HFpEF, citing the extensive preclinical data and positive Phase 1 study results.

The company's approach, leveraging its target discovery and validation capabilities, has led to the development of TN-301 and other therapies aimed at addressing genetic cardiovascular disorders and common heart conditions. Tenaya is advancing its pipeline with the goal of providing curative therapies for heart disease.

This article is based on a press release statement from Tenaya Therapeutics, Inc.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.